Ibandronate sodium monohydrate

Bezeichnung:Ibandronate sodium monohydrate

CAS-Nr138926-19-9

Englisch Name:Ibandronate sodium monohydrate

CBNumberCB4286017

SummenformelC9H24NNaO8P2

Molgewicht359.23

MOL-Datei138926-19-9.mol

Ibandronate sodium monohydrate physikalisch-chemischer Eigenschaften

Schmelzpunkt	840C (dec)
storage temp.	Keep in dark place,Inert atmosphere,2-8°C
Löslichkeit	Soluble in DMSO (up to at least 25 mg/ml)
Aggregatzustand	solid
Farbe	White
Stabilität	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
Major Application	pharmaceutical (small molecule)
InChI	InChI=1S/C9H23NO7P2.Na.H2O/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);;1H2/q;+1;/p-1
InChIKey	VBDRTGFACFYFCT-UHFFFAOYSA-M
SMILES	C(O)(P([O-])(=O)O)(P(=O)(O)O)CCN(C)CCCCC.O.[Na+]
CAS Datenbank	138926-19-9(CAS DataBase Reference)

Sicherheit

Kennzeichnung gefährlicher	Xn
R-Sätze:	40
S-Sätze:	22-36-24/25
WGK Germany	WGK 3
HS Code	29319090
Speicherklasse	8A - Combustible corrosive hazardous materials
Hazard Classifications	Acute Tox. 4 Oral Aquatic Acute 1 Aquatic Chronic 1 Eye Dam. 1 Skin Corr. 1B STOT RE 2

Gefahreninformationscode (GHS)

Ibandronate sodium monohydrate Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R40:Verdacht auf krebserzeugende Wirkung.
S-Sätze Betriebsanweisung:
S22:Staub nicht einatmen.
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.
Beschreibung
Ibandronate Sodium Monohydrate is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
Ibandronate Sodium Monohydrate inhibits bone resorption as a sodium salt and complexed with technetium Tc 99m for bone imaging. The monophosphonates are not active and the biphosphonates are used in disorders affecting the skeleton such as metastatic disease, asteoporosis and Paget's. Ibandronate Sodium Monohydrate is an inhibitor of FDPS.
Chemische Eigenschaften
[1-Hydroxy-3-(methylpentylamino)-propylidene]bisphosphonic acid sodium salt is White Crystalline Powder
Verwenden
Inhibits bone resorption as a sodium salt and complexed with technetium Tc 99m for bone imaging. The monophosphonates are not active. Biphosphonates are used in disorders affecting the skeleton such as asteoporosis, metastatic disease, and Paget d
Verwenden
An inhibitor of bone resorption
Verwenden
bone resorption inhibitor, anthypercalcemic
Mechanism of action
The action of ibandronate on bone tissue is based on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Pharmakokinetik
Absorption
The absorption of oral ibandronate occurs in the upper gastrointestinal tract. Plasma concentrations increase in a dose-linear manner up to 50 mg oral intake and increases nonlinearly above this dose.
Following oral dosing, the time to maximum observed plasma ibandronate concentrations ranged from 0.5 to 2 hours (median 1 hour) in fasted healthy postmenopausal women. The mean oral bioavailability of 2.5 mg ibandronate was about 0.6% compared to intravenous dosing. The extent of absorption is impaired by food or beverages (other than plain water). The oral bioavailability of ibandronate is reduced by about 90% when BONIVA is administered concomitantly with a standard breakfast in comparison with bioavailability observed in fasted subjects. There is no meaningful reduction in bioavailability when ibandronate is taken at least 60 minutes before a meal. However, both bioavailability and the effect on bone mineral density (BMD) are reduced when food or beverages are taken less than 60 minutes following an ibandronate dose.
Distribution
After absorption, ibandronate either rapidly binds to bone or is excreted into urine. In humans, the apparent terminal volume of distribution is at least 90 L, and the amount of dose removed from the circulation via the bone is estimated to be 40% to 50% of the circulating dose. In vitro protein binding in human serum was 99.5% to 90.9% over an ibandronate concentration range of 2 to 10 ng/mL in one study and approximately 85.7% over a concentration range of 0.5 to 10 ng/mL in another study.
Metabolism
There is no evidence that ibandronate is metabolized in humans.
https://www.accessdata.fda.gov
Einzelnachweise
[1] RUSSELL R G G. Ibandronate: Pharmacology and preclinical studies[J]. Bone, 2006, 38 4: Pages S7-S12. DOI:10.1016/j.bone.2006.01.151

Ibandronate sodium monohydrate Upstream-Materialien And Downstream Produkte

Ibandronate sodium monohydrate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

138926-19-9, Ibandronate sodium monohydrate Verwandte Suche:

Send Inquriy